Dry Eye Syndromes Clinical Trial
Official title:
Umbilical Cord Serum Versus Conventional Eyedrops In Treatment of Moderate To Severe Dry Eye Disease: A Randomized Clinical Trial
Dry eye disease (DED) is a chronic ocular surface disease and the prevalence of DED has been
reported as high as 50%. Recently, The international Dry Eyes Workshop II (DEWS II) defines
dry eye as a "multifactorial disease of the ocular surface characterized by a loss of
homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film
instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory
abnormalities play etiological roles". A study done by Yoon et al. on 31 patients with severe
DED concluded that UCS eye drops are effective and safe in treating severe DED. Studies found
that EGF, TGF-β, VEGF and vitamin A levels were significantly higher in UCS than peripheral
blood serum(PBS) whereas IGF content was significantly higher in PBS than in CBS. Yoon et al.
then conducted another study whereby he compared UCS to AS in treating both Sjögren syndrome
and non- Sjögren syndrome patients with severe dry eyes. They concluded that UCS eye drops
were more effective in decreasing symptoms and keratoepitheliopathy in severe dry eye
syndrome and increasing goblet cell density in Sjögren syndrome compared with AS drops.
Despite proven more effective in treating DED, serum eye drops are not yet widely
manufactured due to a few reasons. This study is chosen because
1. Not many previous clinical trials done related to UCS eye drops.
2. There were only two clinical trials done before to compare the use of UCS eye drops
versus conventional AT eye drops on Hansen's disease and acute ocular chemical burn
injury population.
3. To apply the newer technology of Keratograph® 5M in DED assessment.
4. To initiate a proper standard operating procedure for production as well as delivery of
serum eye drops which allowing out-patient treatment with serum eye drops possible.
This is a prospective, single- blinded randomized clinical trial conducted in University
Kebangsaan Malaysia Medical Centre (UKMMC). Umbilical cord serum will be provided by Pusat
Darah Negara (National Blood Centre), Malaysia. All patients from Ophthalmology Clinic in UKM
Medical Centre from December 2019 till December 2021 will be involved in this study. Patients
who fulfill the inclusion criteria will be included in this study. Informed consent will be
taken and dry eye assessment that includes visual acuity, OSDI score, Schirmer test, NITBUT,
corneal fluorescein staining, TMH and conjunctival injection. The patients will be randomised
into 2 groups; AT eye drops and UCS eye drops.
Human umbilical cord blood samples will be collected from Maternity Hospital, Hospital Kuala
Lumpur with assistance of the nurses from Cord Blood Collection Unit. All maternal blood
samples were collected after the written informed consent from respective parents and
subjected for virology screening.
National Blood Bank has a procedure for virology screening and all collected maternal
umbilical cord bloods will be screened for Hep B Surface Antigen, Anti-HCV Ag/Ab, HIV Ag/Ab,
Syphillis and Cytomegalovirus (CMV) IgM in Transfusion Microbiology Laborator (Accredited by
ISO 15189 and CSL). Method that has been used in the screening as below:
- Hep B Surface Antigen, Anti-HCV, HIV Ag/Ab: Chemiluminescent Microparticle Immunoassay
(CMIA).
- Syphilis : Carbon Antigen (Manual)
- CMV IgM : Electrochemiluminescence Immunoassay (ECLIA)
Whereas, the CB samples are screened for bacteriology screening pre and post processing to
ensure sterility of the product. The serum will be discarded if any of the laboratory results
are positive or reactive.
The collected cord blood (CB) will then be placed in an incubator at the collection centre
until the cord blood samples are sent to National Blood Bank in an ice box with temperature
logger. Once the ice box reached National Blood Bank, MLT will check the temperature logger
and make sure all the temperature data within range (10-26oC) before starting the UCS serum
eye drops production.
CB will be processed in Cord Blood Processing Unit within 24 hours of collection to ensure
retrieval of high quality of bioactive molecules. Laboratory temperature room, humidity and
oxygen will be monitored twice a day. Upon arrival at the processing laboratory, the CB will
then be left at room temperature for about 2 hours to allow the CB to clot completely. After
15 minutes of centrifugation at 3,000 × g, under sterile conditions, the serum fraction will
be carefully separated from the cellular fraction. Separated serum is then transferred to a
tygon tube by using a sterile docking device and diluted to a 20% dilution with balanced salt
solution (BSS) without any antibiotics, and finally sealed into 1-inch segment consisting of
approximately 1 ml serum eye drops. The segmented UCS will then be frozen at -20oC for 3 to 6
months or at -80°C for long term storage.
For safety and quality interest, frozen segments will be transported to UKMMC blood bank
using a transportation box filled with dry ice to ensure UCS are at frozen state and to
maintain the quality of the product until they reach destination. From UKMMC blood bank,
participants will need to bring the frozen UCS eye drops home by transporting them in a
cooler box with ice packs. At home, the frozen UCS eye drops will need to be kept in domestic
freezer. The frozen UCS eye drops must be thawed at room temperature prior to usage and
thereafter stored in the refrigerator at 2-8°C for a maximum of 24 hours. A short instruction
sheet will be provided to participants on UCS usage. There will be no porcine/bovine
materials involved in the whole process.
Statistical analysis will be performed using Statistical Package for Social Science, version
20.0 (SPSS, Inc., Chicago, III., USA) for Windows. Mean value comparisons between study
groups can be performed with the Student's T-test using 2 sided-analysis. Mean value
comparisons for follow up can be analysed with ANOVA. Categorical characteristics can be
analyzed using a Chi-square. Differences are considered statistically significant at P<0.05.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Recruiting |
NCT04701086 -
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
|
N/A | |
Active, not recruiting |
NCT03697876 -
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
|
Phase 1 | |
Terminated |
NCT02815293 -
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT02910713 -
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
|
N/A | |
Completed |
NCT04104997 -
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
|
Phase 1 | |
Recruiting |
NCT02595606 -
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
|
Phase 4 | |
Completed |
NCT01711424 -
An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
|
N/A | |
Completed |
NCT01202747 -
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
|
Phase 2/Phase 3 | |
Completed |
NCT01015209 -
Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers
|
Phase 1 | |
Completed |
NCT00969280 -
Acupuncture for Dry Eye Syndrome
|
Phase 3 | |
Completed |
NCT00739713 -
Effects of Sea Buckthorn Oil on Dry Eye
|
N/A | |
Completed |
NCT00756678 -
Efficacy and Acceptability of Two Lubricant Eye Drops
|
Phase 4 | |
Completed |
NCT01496482 -
Comparison of Evaporimetry With the Established Methods of Tear Film Measurement
|
N/A | |
Completed |
NCT00370747 -
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00349440 -
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
|
Phase 4 | |
Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT02871440 -
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT05042960 -
Computer Screen Properties Study
|
N/A |